Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

BACKGROUND: This phase Ib study evaluated afatinib plus vinorelbine in patients with advanced solid tumours overexpressing epidermal growth factor receptor (EGFR) and/or human EGFR 2 (HER2). METHODS: Maximum tolerated doses (MTDs) were determined for afatinib (20, 40 or 50 mg, once daily) combined w...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahleda, Rastislav, Varga, Andrea, Bergé, Yann, Soria, Jean-Charles, Schnell, David, Tschoepe, Inga, Uttenreuther-Fischer, Martina, Delord, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808039/
https://www.ncbi.nlm.nih.gov/pubmed/29337963
http://dx.doi.org/10.1038/bjc.2017.436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808039/
https://www.ncbi.nlm.nih.gov/pubmed/29337963
http://dx.doi.org/10.1038/bjc.2017.436

Ejemplares similares